
                      Download 8-K Special Filing Report
                    
                    
                      Original filing index
                    

Announcement: ACRV 8-K Special Filing

Analyst Summary: 

Acrivon Therapeutics published a press release about their latest financial results. The company's proprietary AP3 precision medicine platform records predictive proteomics in patie...

$ACRV reports positive financial results and advances in precision medicine pipeline

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/d385129d8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/0001193125-23-068545-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 2.02 Item 7.01 Item 9.01

Acrivon Therapeutics Inc

Analyst Summary: 

Acrivon Therapeutics published a press release about their latest financial results. The company's proprietary AP3 precision medicine platform records predictive proteomics in patients to select the right drug for cancer treatment. Acrivon also announced their pipeline, which includes a drug-tailored biopsy test, ACR-368, to increase the overall response rate in single gene driver mutations or known synthetic lethal context. The company has achieved significant progress in clinical trials with an acceptable safety profile in over 1,000 patients. The significant success of Acrivon’s drug-tailored biopsy test and an extensive pipeline of drugs under development boost the company's market position. The company is backed by top-tier investors and has received FDA approval for mass spectrometry. Investors